Results 81 to 90 of about 56,829 (249)

Risk Factors for Cutaneous Immune‐Related Adverse Events in the Japanese Population: A Retrospective Single‐Center Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitor (ICI)‐driven alterations in the immune system can induce immune‐related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese
Tomoya Watanabe   +4 more
wiley   +1 more source

Invasive Meningococcal Disease in a Patient With Complement 7 Deficiency

open access: yesJournal of General and Family Medicine
Neisseria meningitidis can cause invasive meningococcal disease (IMD). Individuals with primary complement deficiencies are at a higher risk of developing IMD. However, cases of IMD associated with complement deficiency have rarely been reported in Japan.
Hiroaki Nishioka   +2 more
doaj   +1 more source

Early Intervention Effects and Risk Factors for Residual Skin Changes in Infantile Hemangiomas

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Infantile hemangioma (IH) characteristically progresses through proliferative, involuting, and involuted phases, and typically undergoes spontaneous regression after the age of five. Therefore, the traditional management strategy has been based on a “wait‐and‐see policy”.
Kayoko Okuda   +4 more
wiley   +1 more source

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

open access: yesAddiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski   +2 more
wiley   +1 more source

A Painful Purpuric Rash in a Febrile Smoker

open access: yes
JEADV Clinical Practice, EarlyView.
Eugerta Dilka   +3 more
wiley   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres   +19 more
wiley   +1 more source

From haemostasis to immunity: The expanding frontiers of platelet biology

open access: yesBritish Journal of Haematology, EarlyView.
Platelets are versatile cells whose functions extend far beyond haemostasis and thrombosis, actively regulating innate and adaptive immunity, angiogenesis, lymphangiogenesis, liver regeneration, atherosclerosis and tumour metastasis. This demonstrates their central role in various physiological processes and multiple life‐threatening diseases ...
Xun Grace Wu, Nicole Tomei, Heyu Ni
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams   +3 more
wiley   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He   +11 more
wiley   +1 more source

Histopathologic Characterization of Cutaneous Oxalosis Mimicking Calciphylaxis: Diagnostic Pitfalls and Polarized Light Evaluation

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous oxalosis is an uncommon manifestation of primary hyperoxalosis, which can often resemble other cutaneous manifestations of end stage renal disease (ESRD), particularly calciphylaxis. We report the case of a 46 year old female with primary hyperoxaluria type one (PH1) believed to be well‐controlled on lumasiran, a small interfering ...
Shrina Patel   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy